Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249621 · ClinicalTrials.gov registry record · Phase 1
A Randomized Phase 1 of of MZE001 in Healthy Volunteers
A Phase 1 study of Healthy, sponsored by Maze Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
- 1
- Study location
NCT05249621: Completed Phase 1 study of Healthy, sponsored by Maze Therapeutics.
NCT05249621 is a Phase 1 study of Healthy that has completed, run by Maze Therapeutics. The registered enrollment target is 121 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05249621, a Phase 1 study of Healthy, has completed, sponsored by Maze Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.
Primary Outcome
Occurrence of adverse events, serious adverse events, adverse events of special interest
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MZE001
Study Locations (1)
California
- Orange County Research Center - Tustin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
What the finished NCT05249621 record still lists
NCT05249621 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05249621 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05249621 about?
NCT05249621 is a clinical study titled "A Randomized Phase 1 of of MZE001 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.
What is the current status of trial NCT05249621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2022-02-07. Estimated completion is 2022-12-21.
What conditions does trial NCT05249621 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05249621?
The interventions under investigation include: Placebo (DRUG), MZE001 (DRUG).
Who is sponsoring clinical trial NCT05249621?
This trial is sponsored by Maze Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05249621 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05249621's enrollment target sits among peer trials
121 181st of 1090 higher than 910 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI